Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?

18 Nov 2019

• By Brian Yang

NIFDC'S FOURTH CHINA GENE THERAPY FORUM IN BEIJING 18-19 OCTOBER • Source: Shutterstock

Related Content

China Tightens Clinical Trial Oversight Post Gene-Edited Babies Scandal

01 Mar 2019

Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research

12 Jun 2019

China's Draft Cell Therapy Guidelines Draws Concern From Industry

09 Apr 2019

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

23 Oct 2019

Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved

30 Sep 2019

Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem

10 Dec 2019

Made In China Gene Therapy A Father's Quest To Save Son With UltraRare Condition

05 Aug 2019

Related Companies

Ocugen Inc.

Spark Therapeutics, Inc.

Additional Topics

China Asia Pacific Gene Therapy BioPharmaceutical

More from China

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.